期刊
CANCER DETECTION AND PREVENTION
卷 28, 期 2, 页码 114-118出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cdp.2003.12.006
关键词
tumor-associated antigen (TAA); autoantibody; cancer diagnosis
类别
资金
- NCI NIH HHS [CA56956] Funding Source: Medline
- NCRR NIH HHS [5G12RR08124] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA056956] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR008124] Funding Source: NIH RePORTER
Cancer sera contain antibodies which react with a unique group of autologous cellular antigens called tumor-associated antigens (TAAs). Cancer has long been recognized as a multi-step process which involves not only genetic changes conferring growth advantage but also factors which disrupt regulation of growth and differentiation. It is possible that some of these factors could be identified and their functions evaluated with the aid of autoantibodies arising during tumorigenesis. The multi-factorial and multi-step nature in the molecular pathogenesis of human cancers must be taken into account in both the design and interpretation of studies to identify biomarkers which will be useful for early detection of cancer. Our recent studies suggest that the combination of antibodies against a group of TAAs might acquire higher sensitivity for diagnosis of cancer. It is conceivable that autoantibody profiles involving different panels or arrays of TAAs might be developed in the future and the results could be useful for cancer diagnosis. (C) 2004 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据